Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as the sole bookrunner for the public offering and acted as the exclusive placement agent for the concurrent private placement.
The offering of these securities in the public offering will be made only by means of a written prospectus. A copy of the prospectus related to the offering may be obtained from Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC if requested by email at firstname.lastname@example.org or by phone at 646-975-6957.
A registration statement relating to the securities being sold in the public offering has been filed with, and was declared effective by, the U.S. Securities and Exchange Commission.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described above nor shall there be any sale of the securities described above in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Certain of the statements made in this press release are forward looking, such as those, among others, relating to BeyondSpring's expectations regarding the completion of the proposed public offering and the concurrent private placement. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the anticipated amount needed to finance the company's future operations, unexpected results of clinical trials, delays or denial in regulatory approval process, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
To read more Press Release articles, click here.